Unlocking the Potential of K-RAS Mutations in Cancer Therapy| Mark Erlander, CEO, Cardiff Oncology Inc. 00:10:00
In a podcast interview, Mark Erlander, CEO of a clinical-stage biotechnology company, discusses his transition from a PhD in neuroscience to leading an oncology company, emphasizing the importance of following passion and taking calculated risks. Erlander highlights the company's mission to develop new cancer treatment options and shares insights into their drug development programs targeting leukemia, prostate cancer, and colorectal cancer with K-RAS mutations.
